MBX Biosciences added a once-monthly triple G agonist prodrug candidate to its pipeline, extending its push in endocrinology. The move follows the start this year of a Phase 3 trial for its once-weekly PTH therapy in chronic hypoparathyroidism.
published
MBX Biosciences added a once-monthly triple G agonist prodrug candidate to its pipeline, extending its push in endocrinology. The move follows the start this year of a Phase 3 trial for its once-weekly PTH therapy in chronic hypoparathyroidism.
Latest documented BWB result
$APP market result
Exit $APP Sold Puts for a nice profit and then sold more Puts - this time the $325's for $3.97
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.